Acrivon Therapeutics, a clinical-stage biotech, centers its drug discovery on the innovative AP3 phosphoproteomics platform, enabling pathway activity profiling within tumor cells for precision oncology. While it has sustained operating losses characteristic of its early development stage, the company shows disciplined cash management with a strong liquidity position as of year-end 2025. Clinical progress, particularly in the registrational Phase 2b trial of ACR-368 and Phase 1 activity of ACR-2316, underpins future value creation but is subject to regulatory and companion diagnostic approval risks. Monitoring upcoming trial data readouts and adequate funding rounds will be crucial for sustaining its developmental runway.